文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

NLRC4炎症小体通过连接表观遗传重编程与先天免疫信号驱动骨髓增生异常综合征

The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling.
PubMed 文献 · Blood Adv · 2026-07-24

骨髓增生异常综合征(MDS)常伴慢性炎症,但其炎症与先天免疫信号失调机制未明。本研究在Tet2缺陷小鼠中发现NLRC4炎症小体通路激活驱动MDS发生,而敲除Nlrc4可减轻MDS并改善生存,揭示了MDS相关炎症的新机制与靶点。

要点

  • Tet2缺陷小鼠呈现高炎症状态,LPS可进一步加剧。
  • NLRC4炎症小体激活驱动Tet2缺陷造血干祖细胞耗竭与MDS发生。
  • 敲除Nlrc4可 impair MDS发展并改善Tet2缺陷小鼠生存。

核心结论

  • NLRC4炎症小体通路激活是Tet2缺陷小鼠MDS发生的关键驱动因素,敲除Nlrc4可减轻MDS并改善生存。

研究设计与样本

  • 研究采用Tet2缺陷小鼠及嵌合小鼠模型,观察炎症状态与MDS发展,并测试Nlrc4敲除的影响。

主要发现

  • Tet2缺陷小鼠出现高炎症状态,LPS诱导的炎症可进一步加剧该状态。
  • 慢性炎症短暂促进Tet2缺陷造血干祖细胞自我更新与髓系分化,但最终加速HSC耗竭并触发MDS。
  • Nlrc4缺失可 impair Tet2缺陷小鼠的MDS发展并改善其生存。

临床怎么用

  • NLRC4炎症小体通路可作为MDS相关炎症管理的潜在靶点,但尚需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS), which are hematopoietic stem cell malignancies, are often accompanied by signs of chronic inflammation, that can in turn drive the pathogenetic process. The precise mechanisms dysregulating inflammatory and innate immune signaling in MDS hematopoietic stem and progenitor cells (HSPCs) remain under investigation. We report that mice lacking Tet2 developed a hyper-inflammatory state, which can be further fueled by LPS-induced inflammation. This chronic inflammation temporarily promotes the self-renewal and myeloid differentiation of Tet2-deficient HSPCs; however, it ultimately accelerates HSC exhaustion and triggers MDS development in chimeric mouse models. Driving this phenotype was the activation of the NLRC4 inflammasome pathway. Notably, Nlrc4 depletion in Tet2-deficient mice impaired MDS development and improved the survival of these mice. These findings uncover a novel mechanistic basis for the MDS-associated inflammation and provide new targeting opportunities in its management.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chen C, Liu F, Arif T, et al. The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling. Blood Adv. 2026. PMID: 42498284. doi:10.1182/bloodadvances.2026020095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。